BioCentury | Nov 19, 2020
Product Development

COVID-19 vaccines that could report Phase III data before Moderna, Pfizer-BioNTech products become broadly available

...AZD1222 (ChAdOx1 nCoV-19): a 40,000-subject U.S. trial and a 10,000-subject study in Brazil. Considering the pace...
BioCentury | Nov 14, 2020

Innovation in a hurry: China biotechs see a fast track to global stage – survey

...need global deals to accelerate at a pace...
...products, in order to grow at a pace... five or more per year —a pace...
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

Vaxxinity aims to disrupt the biologics market with a vaccine platform that replaces mAbs for chronic disease by inducing patients’ immune systems to manufacture therapeutic antibodies in vivo. But...
BioCentury | Nov 4, 2020

Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero

...Tempero Bio and we plan to keep pace...
BioCentury | Oct 31, 2020
Product Development

ICER’s influence on payers could translate to a seat at the table for government drug reviews

As its influence grows among payers and biopharmas, ICER should have a role to play in most price regulation scenarios that play out under the next administration, regardless of who’s at the helm. Whether...
BioCentury | Oct 17, 2020

CHMP’s October recommendations

EMA’s CHMP has backed autologous cells therapies Tecartus, from Gilead, and Lebmeldy, from Orchard, in its October set of opinions. The agency recommended conditional marketing approval for Tecartus brexucabtagene autoleucel from the Kite Pharma Inc....
BioCentury | Oct 14, 2020
Management Tracks

Anderson joining Sofinnova Partners to bridge European biotechs to public markets

...Veteran investor to manage French firm’s crossover fund as IPOs continue to price at record pace...
BioCentury | Oct 7, 2020

With life sciences now a ‘core’ investment area, General Atlantic picks a global head By Paul Bonanos, Associate Editor Growth equity firm General Atlantic has picked up the pace...
BioCentury | Oct 2, 2020

Election volatility may drive investors toward low-risk opportunities in 4Q

...thing that might stop or slow the pace...
BioCentury | Sep 18, 2020

Lava’s $83M series C exemplifies evolution of Novo Ventures’ investing

...Danish firm has dramatically increased pace, size of investments By Stephen hansen, associate editor Over the...
...hansen, associate editor Over the past few years Novo Ventures has been ramping up the pace...
Items per page:
1 - 10 of 1152